Eunjee Lee

Dr. Eunjee Lee

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
YLYu Liu
Yu Liu
HYHaocheng Yu
Haocheng Yu
SYSeungyeul Yoo
Seungyeul Yoo
ELEunjee Lee
Eunjee Lee
ALAlessandro Laganà
Alessandro Laganà
JZJun Zhu
Jun Zhu
Multiple myeloma (MM) is the second most prevalent hematological cancer. MM is a complex and heterogeneous disease, and thus, it is essential to leverage omics data from large MM cohorts to understand the molecular mechanisms underlying MM tumorigenesis, progression, and drug responses, which may aid in the development of better treatments. In this study, we analyzed gene expression, copy number variation, and clinical data from the Multiple Myeloma Research Consortium (MMRC) dataset and constructed a multiple myeloma molecular causal network (M3CN). The M3CN was used to unify eight prognostic gene signatures in the literature that shared very few genes between them, resulting in a prognostic subnetwork of the M3CN, consisting of 178 genes that were enriched for genes involved in cell cycle (fold enrichment = 8.4, p value = 6.1 × 10−26). The M3CN was further used to characterize immunomodulators and proteasome inhibitors for MM, demonstrating the pleiotropic effects of these drugs, with drug-response signature genes enriched across multiple M3CN subnetworks. Network analyses indicated potential links between these drug-response subnetworks and the prognostic subnetwork. To elucidate the structure of these important MM subnetworks, we identified putative key regulators predicted to modulate the state of these subnetworks. Finally, to assess the predictive power of our network-based models, we stratified MM patients in an independent cohort, the MMRF-CoMMpass study, based on the prognostic subnetwork, and compared the performance of this subnetwork against other signatures in the literature. We show that the M3CN-derived prognostic subnetwork achieved the best separation between different risk groups in terms of log-rank test p-values and hazard ratios. In summary, this work demonstrates the power of a probabilistic causal network approach to understanding molecular mechanisms underlying the different MM signatures.

28 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KIKoichi Ito
Koichi Ito
IHIbuki Harada
Ibuki Harada
CMCriseyda Martinez
Criseyda Martinez
KSKatsutoshi Sato
Katsutoshi Sato
ELEunjee Lee
Eunjee Lee
HIHanna Y. Irie
Hanna Y. Irie
Epithelial–mesenchymal transition (EMT) in cancer promotes metastasis and chemotherapy resistance. A subset of triple-negative breast cancer (TNBC) exhibits a mesenchymal gene signature that is associated with poor patient outcomes. We previously identified PTK6 tyrosine kinase as an oncogenic driver of EMT in a subset of TNBC. PTK6 induces EMT by stabilizing SNAIL, a key EMT-initiating transcriptional factor. Inhibition of PTK6 activity reverses mesenchymal features of TNBC cells and suppresses their metastases by promoting SNAIL degradation via a novel mechanism. In the current study, we identify membrane-associated RING-CH2 (MARCH2) as a novel PTK6-regulated E3 ligase that promotes the ubiquitination and degradation of SNAIL protein. The MARCH2 RING domain is critical for SNAIL ubiquitination and subsequent degradation. PTK6 inhibition promotes the interaction of MARCH2 with SNAIL. Overexpression of MARCH2 exhibits tumor suppressive properties and phenocopies the effects of SNAIL downregulation and PTK6 inhibition in TNBC cells, such as inhibition of migration, anoikis resistance, and metastasis. Consistent with this, higher levels of MARCH2 expression in breast and other cancers are associated with better prognosis. We have identified MARCH2 as a novel SNAIL E3 ligase that regulates EMT and metastases of mesenchymal TNBC. Significance: EMT is a process directly linked to drug resistance and metastasis of cancer cells. We identified MARCH2 as a novel regulator of SNAIL, a key EMT driver, that promotes SNAIL ubiquitination and degradation in TNBC cells. MARCH2 is oncogene regulated and inhibits growth and metastasis of TNBC. These insights could contribute to novel strategies to therapeutically target TNBC.

1 July 2019 in GigaScience
Verified
Journal Article
Open access
PDF file
ELEunjee Lee
Eunjee Lee
SYSeungyeul Yoo
Seungyeul Yoo
WWWenhui Wang
Wenhui Wang
ZTZhidong Tu
Zhidong Tu
JZJun Zhu
Jun Zhu
Data errors, including sample swapping and mis-labeling, are inevitable in the process of large-scale omics data generation. Data errors need to be identified and corrected before integrative data analyses where different types of data are merged on the basis of the annotated labels. Data with labeling errors dampen true biological signals. More importantly, data analysis with sample errors could lead to wrong scientific conclusions. We developed a robust probabilistic multi-omics data matching procedure, proMODMatcher, to curate data and identify and correct data annotation and errors in large databases. Application to simulated datasets suggests that proMODMatcher achieved robust statistical power even when the number of cis-associations was small and/or the number of samples was large. Application of our proMODMatcher to multi-omics datasets in The Cancer Genome Atlas and International Cancer Genome Consortium identified sample errors in multiple cancer datasets. Our procedure was not only able to identify sample-labeling errors but also to unambiguously identify the source of the errors. Our results demonstrate that these errors should be identified and corrected before integrative analysis. Our results indicate that sample-labeling errors were common in large multi-omics datasets. These errors should be corrected before integrative analysis.

28 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MWMaximillian Westphal
Maximillian Westphal
ELEunjee Lee
Eunjee Lee
ESEric E. Schadt
Eric E. Schadt
Giselle L. Saulnier-ShollerGiselle L. Saulnier-Sholler
Giselle L. Saulnier-Sholler
JZJun Zhu
Jun Zhu
Medulloblastoma (MB) is the most common pediatric embryonal brain tumor. The current consensus classifies MB into four molecular subgroups: sonic hedgehog-activated (SHH), wingless-activated (WNT), Group 3, and Group 4. MYCN and let-7 play a critical role in MB. Thus, we inferred the activity of miRNAs in MB by using the ActMiR procedure. SHH-MB has higher MYCN expression than the other subgroups. We showed that high MYCN expression with high let-7 activity is significantly associated with worse overall survival, and this association was validated in an independent MB dataset. Altogether, our results suggest that let-7 activity and MYCN can further categorize heterogeneous SHH tumors into more and less-favorable prognostic subtypes, which provide critical information for personalizing treatment options for SHH-MB. Comparing the expression differences between the two SHH-MB prognostic subtypes with compound perturbation profiles, we identified FGFR inhibitors as one potential treatment option for SHH-MB patients with the less-favorable prognostic subtype.

28 March 2024
Verified
Other
Open access
PDF file
KIKoichi Ito
Koichi Ito
IHIbuki Harada
Ibuki Harada
CMCriseyda Martinez
Criseyda Martinez
KSKatsutoshi Sato
Katsutoshi Sato
ELEunjee Lee
Eunjee Lee
HIHanna Y. Irie
Hanna Y. Irie
Figure S8 shows effect of MARCH2 shRNA expression on growth of MDA-MB231 cells

28 March 2024
Verified
Other
Open access
PDF file
KIKoichi Ito
Koichi Ito
IHIbuki Harada
Ibuki Harada
CMCriseyda Martinez
Criseyda Martinez
KSKatsutoshi Sato
Katsutoshi Sato
ELEunjee Lee
Eunjee Lee
HIHanna Y. Irie
Hanna Y. Irie
Figure S6 shows prognostic significance of MARCH2 levels in different cancer types